---
schema_version: "secwatch.filing_event.v1"
accession: "0001737287-23-000089"
form_type: "8-K"
ticker: "ALLO"
cik: "0001737287"
company_name: "Allogene Therapeutics, Inc."
filed_at: "2023-11-02T23:59:59+00:00"
generated_at: "2026-06-09T00:40:18.991435+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Allogene reports Q3 net loss $61.3M; cash $497.7M; ALPHA2 on track

## Summary
- Net loss of $61.3M ($0.37/sh) for Q3 2023; R&D expense $46.0M, G&A $17.0M.
- Cash, equivalents and investments $497.7M as of Sept 30, 2023; runway into 2H 2025.
- 2023 guidance: cash use ~$230M; GAAP op. expense ~$340M incl. ~$80M stock comp.
- ALPHA2 Phase 2 trial for ALLO-501A in LBCL enrolling; completion expected 1H 2024, data by end 2024.
- New CFO Geoffrey Parker and General Counsel Earl Douglas appointed.

## SEC filing metadata
- accession: 0001737287-23-000089
- form_type: 8-K
- ticker: ALLO
- cik: 0001737287
- company_name: Allogene Therapeutics, Inc.
- filed_at: 2023-11-02T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1737287/000173728723000089/0001737287-23-000089-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1737287/000173728723000089/allo-20231102.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001737287-23-000089
- JSON: https://secwatch.observer/filing/0001737287-23-000089.json
- Plain text: https://secwatch.observer/filing/0001737287-23-000089.txt

## Key facts
- Earnings Releases
  Allogene Therapeutics, Inc. reported financial results for for the quarter ended September 30, 2023.
  - Period: for the quarter ended September 30, 2023
  - Result: reported results
  source text: Allogene Therapeutics, Inc. (the “Company”) provided a corporate update and announced its financial results for the quarter ended September 30, 2023 in the press release attached hereto as Exhibit 99.1, which is incorporated herein by reference.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1737287/000173728723000089/0001737287-23-000089-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.